Bristol-Myers will pay Facet $15M milestone fee for cancer drug

01/11/2010 | Boston Globe (tiered subscription model), The

Facet Biotech will get a milestone payment of $15 million from Bristol-Myers Squibb after it started enrolling patients into a Phase II trial of elotuzumab, a multiple myeloma drug. Meanwhile, Bristol-Myers decided not to expand its development deal with Facet for PDL241, an experimental treatment for immune system disorders.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA